Closed-Loop Insulin Delivery Promising in T1DM Pregnancy

Comparable glucose control, less hypoglycemia vs. sensor-augmented pump tx in pregnant women

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

FRIDAY, March 16, 2018 (HealthDay News) -- For pregnant women with type 1 diabetes, a closed-loop system is associated with comparable glucose control and significantly less hypoglycemia than sensor-augmented pump (SAP) therapy, according to a study published online March 13 in Diabetes Care.

Zoe A. Stewart, from the University of Cambridge in the United Kingdom, and colleagues recruited 16 pregnant women to an open-label randomized trial. Participants completed 28 days of closed-loop and SAP insulin delivery separated by a washout period; for up to six weeks postpartum, participants could continue to use the closed-loop system.

The researchers found that the proportion of time with glucose levels within target was comparable for the closed-loop and SAP insulin delivery periods (62.3 versus 60.1 percent). There was also no difference in the mean glucose (131.4 versus 131.4 mg/dL) and time spent hyperglycemic >140 mg/dL (36.6 versus 36.1 percent). Significantly fewer hypoglycemic episodes (median, 8.0 versus 12.5), and less time at <63 mg/dL (1.6 versus 2.7 percent) occurred during closed-loop; the rates of hypoglycemia <50 mg/dL (0.24 versus 0.47 percent) and low blood glucose index (1.0 versus 1.4) were significantly lower. During closed-loop therapy there was significantly less nocturnal hypoglycemia (1.1 versus 2.7 percent).

"Larger, longer duration multicenter trials are now indicated to determine clinical efficacy of closed-loop insulin delivery in T1D pregnancy and the impact on neonatal outcomes," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries; several authors reported related patents and patent applications.

Abstract/Full Text (subscription or payment may be required)

Last Updated: